معرفی
Markus Haapala serves as a University Researcher at the Division of Pharmaceutical Chemistry and Technology within the Faculty of Pharmacy at the University of Helsinki. He acts as a supervisor for the Doctoral Programme in Materials Research and Nanosciences and leads research in microfluidics, 3D-printed organ-on-chip systems, and pharmaceutical analysis under the Chemical Microsystems Lab supervised by Tiina Sikanen.
His research focuses on developing microfluidic platforms for drug metabolism studies, extracellular vesicle analysis, and toxicity screening. Key methodologies include mass spectrometry integration, 3D printing for microdevice fabrication, and organ-on-chip modeling of hepatocyte and cardiomyocyte functions. Recent work emphasizes cytochrome P450 activity monitoring and bacterial biofilm modeling using thiol-ene polymers.
His 15 most recent publications (2023-2025) demonstrate strong concentration in microfluidic organ-on-chip applications, with recurring themes in extracellular vesicle quantitation, drug metabolite production, and biofilm formation. The work bridges pharmaceutical chemistry, microengineering, and toxicology, frequently utilizing 3D printing to replace traditional cleanroom fabrication.
Award highlights include:
- Finnish Mass Spectrometry Society Prize for High-Level Doctoral Dissertation (2011)
- University of Helsinki Prize for High-Level Doctoral Dissertation (March 25, 2011)
Haapala actively supervises doctoral candidates (Jéssica Amorim, Gowtham Sathyanarayanan) and master's students (Laura Sirviö), while participating in major research projects including PRINTOX (3D-printed organ-on-chip platforms) and EMiRa (enzyme microreactors for drug interaction studies). His work has attracted significant media coverage regarding 3D printing applications in chemical research.
He operates within the Chemical Microsystems Lab, collaborating closely with Tiina Sikanen's team on microfluidic device development. Current efforts focus on scaling organ-on-chip platforms for high-throughput drug screening and integrating real-time metabolic activity monitoring.
